+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 100Years
All Genders
ID07779460

Comparing Effectiveness and Costs of Kesimpta Ofatumumab Versus Ocrevus Ocrelizumab in Multiple Sclerosis A Retrospective Real-World Study

Led by Novartis Pharmaceuticals · Updated on 2026-08-21

7466

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the real-world effectiveness and economic impact of two treatments, ofatumumab OMB and ocrelizumab OCR, in people diagnosed with multiple sclerosis MS in the United States. The study aims to compare how well these treatments reduce the annualized relapse rate ARR and to assess related healthcare use and costs. Data will be gathered from de-identified healthcare claims collected over time to better understand these outcomes. The study includes multiple groups patients new to treatment who start OMB or OCR without prior disease-modifying therapy DMT use in the past year, as well as all patients starting OMB or OCR regardless of previous treatment. Participants are grouped based on their treatment claims, and the study observes their healthcare utilization and relapse events over approximately five years and four months. Participants health records will be analyzed to measure relapse rates, healthcare visits, and costs yearly. The main focus is on treatment-naive patients, with several secondary measures including time to first relapse and total healthcare expenses. Continuous healthcare enrollment and persistent medication use for at least six months are required. The study spans a long period, allowing in-depth observation of treatment effects and economic burden in real-world settings.

CONDITIONS

Brief Title

A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here